Targeted therapy and radiation for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy (atezolizumab), targeted therapy (bevacizumab), and targeted radiation for advanced liver cancer that cannot be surgically removed. The goal is to see if this approach helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 19 and 80 years old.
- Your liver function is good (Child-Pugh class A).
- You are able to perform daily activities without much help (ECOG 0-1).
- You have been diagnosed with advanced hepatocellular carcinoma that cannot be removed by surgery.
- Your tumor(s) are small enough and positioned so that radiation can be given safely.
- You do not have untreated or high-risk varices in your stomach or esophagus, serious uncontrolled medical conditions, a history of liver transplant, or autoimmune liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
This trial studies how well atezolizumab and bevacizumab work together with radiation to treat advanced hepatocellular carcinoma (liver cancer) that has spread into the portal vein. It may help shrink or control tumors and improve outcomes, but you must meet several safety and cancer-location criteria.
This trial tests a combination of carbon ion radiation therapy with two drugs, atezolizumab and bevacizumab, for people with advanced liver cancer that cannot be surgically removed. The goal is to see if this approach is safe and effective.
This Phase 1 trial tests how well a combination treatment works for liver cancer that cannot be removed with surgery or other local treatments. It combines two immune/targeted medicines with a focused type of radiation (SBRT) to control the tumors.
This trial tests combining radiation therapy with immunotherapy (AtezoBev) before a liver transplant for advanced liver cancer. The goal is to see if this approach can shrink tumors and make transplant possible for more people.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.